Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,totalCashFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,HJLI,40874236.0,8513660,1089716,,-2377895,,-2377895,1295747,0,-2385463,-2385463,,,,,,0,0,2385463,0,7568,,-2377895,-2377895,111348343.0,1477894.0,40874236.0,33000.0,42352130.0,85.0,-70474192.0,34993.0,41039182.0,1393312.0,878270.0,41438867.0,308881.0,-402781.0,-126482.0,-199966.0,3270000.0,-2797505.0,-2671023.0,107502.0,-3270000.0,202117.0,-126482.0,,40045555.0,en-US,US,EQUITY,True,Delayed Quote,USD,-1.5228412,7.6737 - 7.91,7.88,0.0,0.0,8,18,finmb_28089740,NasdaqCM,USD,715784,194685,2.7700005,0.55511034,4.99 - 17.68,-9.92,-0.56108594,4.99,17.68,1606694400,1591635660,1591635660,1591635660,-4.466,-1.44,-1.55,-5.006452,-14400000,5.055,6.6145716,1.1454287,0.17316748,6.4964857,1.2635145,2,"Hancock Jaffe Laboratories, Inc","Hancock Jaffe Laboratories, Inc.",7.76,1630526402,-0.119999886,7.85,7.91,7.6737,89412,PRE,NCM,us_market,0.194492,66066004,-5.388889,1.5351138,15,America/New_York,EDT,False,False,0,1.5,,,17.68,4.99,6.61,6.5,715.78k,194.69k,8.51M,,6.47M,12.67%,21.37%,545.54k,0.32,7.23%,6.41%,152.18k,,,,,,0.00%,"Nov 29, 2020",,1:25,"Nov 29, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-30.58%,-55.76%,,,,,-11.16M,-12.11M,-4.47,,41.04M,4.82,723.55k,1.77,29.74,5.05,-11.72M,-7.56M,Value,92618,Healthcare,19,"Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.",Irvine,949 261 2900,CA,1609372800,United States,http://www.hancockjaffe.com,86400,70 Doppler,949 261 2992,Medical Devices
t-1,HJLI,43011572.0,8513660,1631795,,-2772886,,-2772886,1176455,0,-2808250,-2808250,,,,,,0,0,2808250,0,35364,,-2772886,-2772886,111107784.0,2043085.0,43011572.0,,45054657.0,85.0,-68096297.0,29843.0,43836687.0,1873921.0,859290.0,44165524.0,709238.0,-681124.0,-24027.0,-620478.0,35097776.0,34502103.0,-3841646.0,103678.0,3270000.0,129164.0,-24027.0,38367776.0,42291603.0,en-US,US,EQUITY,True,Delayed Quote,USD,-1.5228412,7.6737 - 7.91,7.88,0.0,0.0,8,18,finmb_28089740,NasdaqCM,USD,715784,194685,2.7700005,0.55511034,4.99 - 17.68,-9.92,-0.56108594,4.99,17.68,1606694400,1591635660,1591635660,1591635660,-4.466,-1.44,-1.55,-5.006452,-14400000,5.055,6.6145716,1.1454287,0.17316748,6.4964857,1.2635145,2,"Hancock Jaffe Laboratories, Inc","Hancock Jaffe Laboratories, Inc.",7.76,1630526402,-0.119999886,7.85,7.91,7.6737,89412,PRE,NCM,us_market,0.194492,66066004,-5.388889,1.5351138,15,America/New_York,EDT,False,False,0,1.5,,,17.68,4.99,6.61,6.5,715.78k,194.69k,8.51M,,6.47M,12.67%,21.37%,545.54k,0.32,7.23%,6.41%,152.18k,,,,,,0.00%,"Nov 29, 2020",,1:25,"Nov 29, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-30.58%,-55.76%,,,,,-11.16M,-12.11M,-4.47,,41.04M,4.82,723.55k,1.77,29.74,5.05,-11.72M,-7.56M,Value,92618,Healthcare,19,"Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.",Irvine,949 261 2900,CA,1609372800,United States,http://www.hancockjaffe.com,86400,70 Doppler,949 261 2992,Medical Devices
t-2,HJLI,7097856.0,8513660,2277254,,-4374003,,-4374003,1881157,0,-4158411,-4158411,,,,,,0,0,4158411,0,-215592,,-4374003,-4957364,72421242.0,3439979.0,7097856.0,221104.0,10537835.0,25.0,-65323411.0,29843.0,9334584.0,3186233.0,938941.0,9569051.0,1390362.0,416133.0,-27540.0,702209.0,5189128.0,3705581.0,-2613694.0,95979.0,1355588.0,545988.0,-27540.0,6346815.0,6382818.0,en-US,US,EQUITY,True,Delayed Quote,USD,-1.5228412,7.6737 - 7.91,7.88,0.0,0.0,8,18,finmb_28089740,NasdaqCM,USD,715784,194685,2.7700005,0.55511034,4.99 - 17.68,-9.92,-0.56108594,4.99,17.68,1606694400,1591635660,1591635660,1591635660,-4.466,-1.44,-1.55,-5.006452,-14400000,5.055,6.6145716,1.1454287,0.17316748,6.4964857,1.2635145,2,"Hancock Jaffe Laboratories, Inc","Hancock Jaffe Laboratories, Inc.",7.76,1630526402,-0.119999886,7.85,7.91,7.6737,89412,PRE,NCM,us_market,0.194492,66066004,-5.388889,1.5351138,15,America/New_York,EDT,False,False,0,1.5,,,17.68,4.99,6.61,6.5,715.78k,194.69k,8.51M,,6.47M,12.67%,21.37%,545.54k,0.32,7.23%,6.41%,152.18k,,,,,,0.00%,"Nov 29, 2020",,1:25,"Nov 29, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-30.58%,-55.76%,,,,,-11.16M,-12.11M,-4.47,,41.04M,4.82,723.55k,1.77,29.74,5.05,-11.72M,-7.56M,Value,92618,Healthcare,19,"Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.",Irvine,949 261 2900,CA,1609372800,United States,http://www.hancockjaffe.com,86400,70 Doppler,949 261 2992,Medical Devices
t-3,HJLI,4794919.0,8513660,758198,,-1974769,,-1974769,1164089,0,-1922287,-1922287,,,,,,0,0,1922287,0,-52482,,-1974769,-1998628,65743924.0,2247720.0,4794919.0,33000.0,7042681.0,403.0,-60949408.0,29843.0,5629003.0,1915424.0,1035182.0,5977656.0,974229.0,-593127.0,-24965.0,-369756.0,5231626.0,3255022.0,-2591648.0,98538.0,-915994.0,247466.0,-24965.0,5871635.0,4062232.0,en-US,US,EQUITY,True,Delayed Quote,USD,-1.5228412,7.6737 - 7.91,7.88,0.0,0.0,8,18,finmb_28089740,NasdaqCM,USD,715784,194685,2.7700005,0.55511034,4.99 - 17.68,-9.92,-0.56108594,4.99,17.68,1606694400,1591635660,1591635660,1591635660,-4.466,-1.44,-1.55,-5.006452,-14400000,5.055,6.6145716,1.1454287,0.17316748,6.4964857,1.2635145,2,"Hancock Jaffe Laboratories, Inc","Hancock Jaffe Laboratories, Inc.",7.76,1630526402,-0.119999886,7.85,7.91,7.6737,89412,PRE,NCM,us_market,0.194492,66066004,-5.388889,1.5351138,15,America/New_York,EDT,False,False,0,1.5,,,17.68,4.99,6.61,6.5,715.78k,194.69k,8.51M,,6.47M,12.67%,21.37%,545.54k,0.32,7.23%,6.41%,152.18k,,,,,,0.00%,"Nov 29, 2020",,1:25,"Nov 29, 2020","Dec 30, 2020","Jun 29, 2021",0.00%,0.00%,-30.58%,-55.76%,,,,,-11.16M,-12.11M,-4.47,,41.04M,4.82,723.55k,1.77,29.74,5.05,-11.72M,-7.56M,Value,92618,Healthcare,19,"Hancock Jaffe Laboratories, Inc., a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.",Irvine,949 261 2900,CA,1609372800,United States,http://www.hancockjaffe.com,86400,70 Doppler,949 261 2992,Medical Devices
